What happened

Paul Andrew Moore, Zymeworks Inc. (NASDAQ: ZYME) chief scientific officer, sold 39,741 shares on Nov. 13 for about $1.04 million.

The filing says the shares came from 25,000 options exercised that day at $5.82, then sold in three blocks at weighted-average prices of $26.14, $26.09 and $26.04.

Moore held 33,756 shares afterward, and the report also shows 175,000 derivative securities remaining after the option transaction. That leaves a direct stake in place even after the disposal.

Why it matters

The sale trimmed a sizeable position, because the 39,741 shares were about 54.1% of Moore's 73,497-share holding before the trade. That scale matters for holders, since a disposal that large can shift the insider ledger more than a smaller routine sale.

OptimistFi has argued that Zymeworks works if its licensed-asset and multifunctional-biotherapeutics model turns scientific optionality into repeatable partner-funded milestones before cash burn forces dilution. This filing leaves that operating test unchanged and reads as a mixed insider signal, because the sale was paired with same-day option exercise rather than fresh open-market buying.

The report also fixes the mechanics of the trade. Moore exercised 25,000 options and then sold 39,741 shares in three blocks, so the filing shows monetization rather than a clean new purchase or a one-step exit.

For investors, the useful question is whether later filings show more trimming or a stable stake after this monetization. The trade does not change the science story on its own, but it does reduce the direct equity exposure tied to Moore's position.

It also leaves 175,000 derivative securities outstanding, which gives a dated reference point for any later exercise activity. If Moore keeps reducing the position, the insider picture weakens further. If not, this sale looks more isolated.

Explain the financial terms

An open-market trade is a purchase or sale on an exchange at the market price, not a grant, option exercise or private deal.

What's next

The options expire on July 17, 2032, which is the filing's only dated future marker. Any further exercise or sale before then would show whether Moore keeps reducing the position, while no more activity would leave this transaction looking isolated.

That date is the next dated check in the filing. A later filing with more sales would extend the trimming pattern, and a quiet stretch would make this one look more like a one-off cleanup.

Sources checked automatically Nov 16, 2026 · Human review: none
Thesis impactZYME: no published thesis yet.